Inhalation

INH1026

Issue link: https://www.e-digitaleditions.com/i/1546950

Contents of this Issue

Navigation

Page 26 of 43

Inhalation OctOber 2026 25 lation strategies involves understanding of formula- tion composition and process development and their impact on phage viability and aerosolization. is article discusses challenges and highlights formula- tion strategies that may help overcome obstacles to effective inhaled phage delivery. Phages—Structure and antibacterial activity Phages are viruses, consisting of nucleic acids hav- ing a large molecular weight (more than 10 7 g/mol). Structurally, phages have a protein capsid, which encloses genetic material, and a tail. Depending on their morphology, phages are classified into differ- ent families (for example, Myoviridae, Podoviridae and Siphoviridae) having contractile, short and long tails, respectively. e phage tail fibers identify and bind to specific receptors on bacteria (like lipopoly- saccharides, pili or efflux pumps) and subsequently hijack the bacterial replication machinery [10,11]. e phage produces new phage progeny, which are released from the bacterial cells via lysis, leading to bacterial death. erefore, the structure of the phage is important for its antibacterial action. Figure 1 illustrates the lytic cycle of phages. Generally, phage viability is measured in terms of active phage parti- cles and expressed as plaque forming units (PFU). sionate use, for patients with serious life-threatening conditions. Phages are considered to be biologics by the US FDA Center for Biologics Evaluation and Research (CBER) [6]. Among the ongoing phage therapy clinical trials in the US, inhaled delivery is most common for treating respiratory infections. P. aeruginosa is the highly tar- geted bacteria being explored in these clinical trials. Table 1 lists ongoing phage therapy trials for respira- tory infections being conducted in the US. Inhaled phage delivery allows direct administration of phages in the lung lumen and offers easy access to the site of infection. Additionally, systemic degra- dation of phages is minimized and high phage den- sities can be achieved in the lungs, which is critical for antibacterial action [7]. Despite these advantages, phages are extremely sensitive to physical and chem- ical stresses, which can compromise their viability and, in turn, their antibacterial activity. erefore, maintaining phage viability during manufacturing, storage and delivery is important to achieve favorable therapeutic outcomes [8]. Formulation strategies are being developed to stabilize phages and minimize viability loss during delivery. ese strategies include excipient-based stabilization, dry powder formu- lation and encapsulation (using lipid or polymeric nanoparticles) [9]. e application of these formu- Figure 1 Antibacterial action of bacteriophages via the lytic cycle LYTIC CYCLE Phage Bacteria/Host cell Attachment Phage attaches to host cell and injects DNA Penetration Phage DNA circularizes and enters lytic cycle Biosynthesis and Maturation New phage DNA and proteins are synthesized and assembled into virions Lysis Cell lyses, releasing phage virions 4 3 2 1

Articles in this issue

view archives of Inhalation - INH1026